|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/7/2013 9:31:36 AM
CAMBRIDGE, Mass., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that, on January 2, 2013, Aegerion granted stock options to purchase an aggregate of 55,000 shares of common stock to five new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $27.24, the closing price of Aegerion's common stock on the grant date, vests in equal monthly installments over four years, has a ten year term and will be subject to the terms and conditions of a stock option agreement covering the grant.
|
|
|
|
|
|
|
|
|
|
|